세계의 멀티플렉스 어세이 시장 보고서(2025년)
Multiplex Assays Global Market Report 2025
상품코드 : 1824504
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,471,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,354,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,236,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

멀티플렉스 어세이 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 8.2%로 성장할 전망이며, 53억 3,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 자금 조달 증가, 유전학적 및 미생물학적 연구에 대한 정부의 대처, 고령화, 만성질환의 유병률 증가, 다양한 세균 및 바이러스 전염병의 급증에 기인하고 있습니다. 예측 기간 주요 동향은 자금 조달 증가, 유전학적 및 미생물학적 연구에 대한 정부의 대처, 고령화, 만성질환 유병률 증가, 다양한 세균 및 바이러스의 전염병의 급증 등입니다.

향후 5년간의 성장률 8.2%라고 하는 예측은 전회 예측으로부터 0.2%라고 하는 미감소를 반영하고 있습니다. 이 감소는 주로 미국과 타국가 간 관세의 영향 때문입니다. 무역 마찰은 일본과 한국에서 개발된 다중 면역 측정 플랫폼 및 시약 패널의 가격을 상승시켜 바이오마커 분석의 지연과 임상 검사 비용의 상승을 초래하여 미국의 고처리량 다이아그노스틱스 채용을 방해할 수 있습니다. 또한 상호 관세와 무역 긴장 증가 및 제한으로 인한 세계 경제와 무역에 대한 악영향으로 그 영향이 더욱 광범위하게 보일 것입니다.

만성 질환의 이환율 증가는 세계 멀티플렉스 어세이 시장의 성장에 박차를 가하고 있습니다. 멀티플렉스 어세이는 임상 시험에서 질병의 효능을 평가하거나 다양한 질병과 관련된 항체를 검출하는 데 널리 사용됩니다. 예를 들어 2023년 9월 세계보건기구(WHO)가 발표한 보고서에 따르면, 비감염성 질환(NCD)으로도 알려진 만성 질환은 세계 사망의 74%를 차지하며 연간 4,100만 명이 사망하고 있습니다. 그 결과, 만성질환의 유병률 증가는 세계의 멀티플렉스 어세이 시장 수요를 촉진할 것으로 예측됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Multiplex assays are employed to amplify multiple targets in a polymerase chain reaction (PCR) trial, enabling the extraction of additional information from minuscule amounts of proteins or other analyses in a shorter time compared to traditional systems, similar to ELISA. These assays find application in pathogen identification, mutation analysis, RNA discovery, gene discovery analysis, relation analysis, forensic studies, and other scientific endeavors.

The primary types of multiplex assays comprise nucleic acid-based multiplex assays, protein-based multiplex assays, and others. Nucleic acid-based multiplex assays rely on nucleic acids to detect organism-specific DNA or RNA sequences. These tests are generally characterized by specificity and high sensitivity, providing rapid results. Various technologies underpin multiplex assays, including flow cytometry, luminescence, fluorescence detection, multiplex real-time PCR, and other related technologies. Multiplex assays serve diverse applications, including research and development, as well as clinical diagnostics. End-users encompass pharmaceutical and biotechnology companies, hospitals and research institutes, reference laboratories, and other entities involved in scientific research and diagnostics.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The multiplex assays market research report is one of a series of new reports from The Business Research Company that provides multiplex assays market statistics, including multiplex assays industry global market size, regional shares, competitors with multiplex assays market share, detailed multiplex assays market segments, market trends and opportunities, and any further data you may need to thrive in the multiplex assays industry. This multiplex assays market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The multiplex assays market size has grown strongly in recent years. It will grow from $3.67 billion in 2024 to $3.88 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to increased healthcare expenditure, emerging markets growth, rapid technological advances, and a rapid growth in the aging population.

The multiplex assays market size is expected to see strong growth in the next few years. It will grow to $5.33 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to the rise in funding, government initiatives for genetic and microbiological research, aging population, increasing prevalence of chronic diseases and a rapid rise in various bacterial and viral epidemics. Major trends in the forecast period include the rise in funding, government initiatives for genetic and microbiological research, the aging population, the increasing prevalence of chronic diseases, and a rapid rise in various bacterial and viral epidemics.

The forecast of 8.2% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of high-throughput diagnostics by inflating prices of multiplex immunoassay platforms and reagent panels developed in Japan and South Korea, resulting in slower biomarker analysis and higher clinical lab costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing incidence of chronic diseases is fueling growth in the global multiplex assay market. Multiplex assays are widely used in clinical trials to assess disease efficacy and to detect antibodies related to various conditions. For instance, in September 2023, a report by the World Health Organization (WHO) highlighted that chronic diseases, also known as non-communicable diseases (NCDs), are responsible for 74% of global deaths, amounting to 41 million fatalities annually. Consequently, the growing prevalence of chronic diseases is expected to drive demand in the global multiplex assay market.

The market for multiplex assays is expected to be further driven by increased funding from governments and private organizations. Significant investments are being made to develop multiplex assays, especially amid the challenges posed by the COVID-19 pandemic. The surge in COVID-19 testing has led to consolidation and merger activities. For instance, in May 2024, Autonomous Medical Devices Incorporated (AMDI), a U.S.-based biotechnology company, received a $5.2 million grant from the National Institutes of Health (NIH) to finalize its rapid point-of-care (POC) viral testing system. This system employs polymerase chain reaction (PCR), a highly regarded method for amplifying specific DNA sequences, enabling accurate detection of viral genetic material. With its capability to identify even minimal amounts of viral RNA or DNA, the system offers high sensitivity and specificity, making it a valuable tool for diagnosing infections at their early stages.

Companies in the market are actively launching innovative tests based on multiplex assays to fortify their market positions. In May 2022, QuantuMDx Group Limited introduced the Q-POC SARS-CoV-2, Flu A/B, and RSV Assay, a multiplex panel designed to detect SARS-CoV-2, Influenza A, Influenza B, and RSV at the point of need, further showcasing the market's evolution.

Companies in the multiplex assay market are prioritizing new product launches to enhance their market presence. For example, in January 2024, Bio-Rad Laboratories Inc., a U.S.-based company specializing in life science research and clinical diagnostic products, introduced the ddPLEX ESR1 Mutation Detection Kit. This kit is the first ultrasensitive multiplexed digital PCR assay designed specifically for detecting breast cancer mutations in clinical research. It allows for the simultaneous detection and quantification of seven relevant ESR1 mutations in a single well, simplifying the testing process. With an analytical sensitivity of 0.01% variant allele fraction (VAF), it can detect low-frequency mutations, which are crucial in cancer diagnostics. Additionally, the kit is compatible with circulating tumor DNA (ctDNA) from plasma and DNA from formalin-fixed paraffin-embedded (FFPE) tissue samples, offering flexibility in sample types for testing.

In May 2022, CellCarta, a Canada-based precision laboratory services company, acquired Precision Assays for an undisclosed amount. This acquisition aims to expand CellCarta's precision medicine laboratory services by obtaining commercial rights to antibody panels and assays developed by Precision Assays. Through this acquisition, CellCarta enhances its capabilities in next-generation targeted proteomics testing solutions, especially benefiting its pharmaceutical and biotech clients. Precision Assays, a U.S.-based developer, specializes in high-end multiplex quantitative immuno-MRM mass spectrometry-based assays, adding advanced analytical capabilities to CellCarta's service offerings.

Major companies operating in the multiplex assays market include Seegene Inc, DiaSorin SpA, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Abcam Plc, PerkinElmer Inc, Hologic Corporation, Meso Scale Diagnostics, Merck KGaA, Roche Diagnostics India Pvt Ltd, bioMerieux India, Becton Dickinson Private Limited, Danaher Corporation, Johnson & Johnson, Simens Healthcare, Beckman Coulter Inc. India, Ortho Clinical Diagnostics, Sysmex Corporation, Siemens Healthineers Ukraine, TestLine Clinical Diagnostics s.r.o., Cepheid, F. Hoffmann-La Roche Ltd., Hologic, Bayer AG, Cantel Medical Corporation, Meridian Bioscience, Faizyme Laboratories, Alere Inc., Bangs Laboratories Inc, The Merck Group, Takara Bio Inc, Qiagen, Spherotech Inc, Geneaid Biotech Ltd, Rockland Immunochemicals Inc, GenScript Biotech Corporation

North America was the largest region in the multiplex assays market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multiplex assays market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the multiplex assays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The multiplex assays market consists of sales of equipment with technologies that can detect multiple genes such as flow cytometry, fluorescence detection, luminescence, multiplex real-time PCR, and other technologies in multiplex assays. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Multiplex Assays Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on multiplex assays market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for multiplex assays ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The multiplex assays market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Multiplex Assays Market Characteristics

3. Multiplex Assays Market Trends And Strategies

4. Multiplex Assays Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Multiplex Assays Growth Analysis And Strategic Analysis Framework

6. Multiplex Assays Market Segmentation

7. Multiplex Assays Market Regional And Country Analysis

8. Asia-Pacific Multiplex Assays Market

9. China Multiplex Assays Market

10. India Multiplex Assays Market

11. Japan Multiplex Assays Market

12. Australia Multiplex Assays Market

13. Indonesia Multiplex Assays Market

14. South Korea Multiplex Assays Market

15. Western Europe Multiplex Assays Market

16. UK Multiplex Assays Market

17. Germany Multiplex Assays Market

18. France Multiplex Assays Market

19. Italy Multiplex Assays Market

20. Spain Multiplex Assays Market

21. Eastern Europe Multiplex Assays Market

22. Russia Multiplex Assays Market

23. North America Multiplex Assays Market

24. USA Multiplex Assays Market

25. Canada Multiplex Assays Market

26. South America Multiplex Assays Market

27. Brazil Multiplex Assays Market

28. Middle East Multiplex Assays Market

29. Africa Multiplex Assays Market

30. Multiplex Assays Market Competitive Landscape And Company Profiles

31. Multiplex Assays Market Other Major And Innovative Companies

32. Global Multiplex Assays Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Multiplex Assays Market

34. Recent Developments In The Multiplex Assays Market

35. Multiplex Assays Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기